Clinical Topics   /   Oncology

Risk Predictor Guides Breast Cancer Treatment at MHS Facility

by Annette Boyle
June 1, 2018

SAN ANTONIO, TX — Physicians and patients want to do everything possible to minimize the risk of breast cancer recurrence without incurring unnecessary toxicity from chemotherapy. While staging and subtype provide significant indications of risk, some women will progress despite apparently good indicators.

To help optimize decision-making, the MHS relies on a recurrence score to select patients for chemotherapy. The results have been excellent, reported a study released in conjunction with the 2018 American Society of Clinical Oncology Annual Meeting this weekend in Chicago.1

Researchers at the San Antonio Military Medical Center at Fort Sam Houston, TX, described use of an Oncotype DX database over a 10-year span at their facility. The retrospective cohort study analyzed results from 149 patients treated between 2007 and 2017. All but one patient had hormone-positive, node-negative breast cancer, a profile associated with generally good outcomes.

The Oncotype DX breast cancer assay uses 21 genes to analyze tumors to determine risk of recurrence. Scores below 18 predict a low risk of recurrence and indicate that hormone therapy alone will likely suffice. Scores above 30 are associated with higher risk that could be minimized with adjuvant chemotherapy.

The San Antonio cohort included 70 (47%) categorized as low risk, 60 women (41%) considered intermediate risk and 18 patients (12%) classified as high risk. Patients who had hormone negative or HER2 positive tumors were considered high risk.

Researchers found no correlation between patient age, ethnicity or score severity and risk classification. Higher histological grades, larger tumors and higher recurrence rates corresponded to higher risk scores.

Physicians’ recommendations for therapy generally followed the treatment suggested as appropriate by the recurrence score. Chemotherapy was offered to just 7% of the women with low-risk scores. In contrast, 52% of the intermediate-risk women received chemotherapy, as did 100% of those considered high risk.

Five-year progression free survival in this cohort supported the initial risk assessment, at 98.6% for low-risk women and 93.3% for women with intermediate risk. Among high-risk women, five-year progression free survival was 88.2%.


1Wan W, Aden J, Terrazzino S, Villarreal S, Delacruz WP. Application of a 21-gene recurrence score assay in node negative, hormone receptor positive breast cancer in a military treatment facility. 2018 ASCO Annual Meeting. Abstract e12567.

Related Articles

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article


U.S. Medicine Recommends


More From oncology

Oncology

Effective Metrics Help VA Exceed National Goal for Colorectal Cancer Screening

More Than 80% of Patients Meet Recommendations LOS ANGELES—More than four out of five veterans eligible for colorectal cancer screening have been screened, putting the largest healthcare system in the United States among the top... View Article

Oncology

More Options, Better Survival for Veterans With Metastatic Pancreatic Cancer

ALBANY, NY—Pancreatic cancer remains one of the deadliest malignancies in the United States, but new therapies can extend life and improve quality of life for many patients. That is especially the case at the VA,... View Article

Oncology

Military Risks for Ocular Surface Squamous Neoplasia

MIAMI—While a variety of risk factors have been evaluated in ocular surface squamous neoplasia, few studies have assessed risk factors specific to the armed forces veteran population. A report in the journal Eye and Vision... View Article

Oncology

Antibiotics Appear to Inhibit Tumor Activity in CTCL

AARHUS, DENMARK—Do CD4 T cell responses to  Staphylococcus aureus inadvertently enhance neoplastic progression in models of skin cancer and cutaneous T cell lymphoma? A prospective study in the journal Blood examined that question, exploring the... View Article

Oncology

Lower Dose Cisplatin Preferable in Squamous Cell Carcinoma

PHILADELPHIA—Chemoradiotherapy is commonly used for nonoperative treatment of locally advanced head and neck squamous cell carcinoma. The issue, according to a recent study, is that the standard dose of 100 mg/m2 cisplatin every three weeks is... View Article

Facebook Comment

Subscribe to U.S. Medicine Print Magazine

U.S. Medicine is mailed free each month to physicians, pharmacists, nurse practitioners, physician assistants and administrators working for Veterans Affairs, Department of Defense and U.S. Public Health Service.

Subscribe Now

Receive Our Email Newsletter

Stay informed about federal medical news, clinical updates and reports on government topics for the federal healthcare professional.

Sign Up